Phase 2 Trial of Smoothened (SMO) Inhibitor PF-04449913 (PF-04) in Refractory Myelodysplastic Syndromes (MDS)

被引：2
|
作者：
Lancet, Jeffrey E. [1 ]
Komrokji, Rami S. [1 ]
Sweet, Kendra L. [1 ]
Duong, Vu H. [2 ]
McGraw, Kathy L. [1 ]
Zhang, Ling [3 ]
Nardelli, Lisa Ann [1 ]
Ma, Zhenjun [4 ]
Reich, Richard R. [5 ]
Padron, Eric [1 ,6 ]
List, Alan F. [1 ]
机构：
[1] H Lee Moffitt Canc Ctr & Res Inst, Dept Malignant Hematol, Tampa, FL USA
[2] Univ Maryland Sch Med, Dept Med, Baltimore, MD USA
[3] H Lee Moffitt Canc Ctr & Res Inst, Hematopathol & Lab Med, Tampa, FL USA
[4] H Lee Moffitt Canc Ctr & Res Inst, Dept Biostatist & Bioinformat, Tampa, FL USA
[5] H Lee Moffitt Canc Ctr & Res Inst, Dept Biostatist & Bioinformat, Tampa, FL USA
[6] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
来源：
BLOOD | 2016年 / 128卷 / 22期
关键词：
D O I：
10.1182/blood.V128.22.3174.3174
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3174
引用
收藏
页数：5
相关论文
共 50 条
  • [1] Discovery of PF-04449913, a Potent and Orally Bioavailable Inhibitor of Smoothened
    Munchhof, Michael J.
    Li, Qifang
    Shavnya, Andrei
    Borzillo, Gary V.
    Boyden, Tracey L.
    Jones, Christopher S.
    LaGreca, Susan D.
    Martinez-Alsina, Luis
    Patel, Nandini
    Pelletier, Kathleen
    Reiter, Larry A.
    Robbins, Michael D.
    Tkalcevic, George T.
    ACS MEDICINAL CHEMISTRY LETTERS, 2012, 3 (02): : 106 - 111
  • [2] EFFECT OF A STRONG INDUCER ON THE PLASMA PHARMACOKINETICS (PK) OF THE SMOOTHENED (SMO) INHIBITOR GLASDEGIB (PF-04449913).
    Shaik, M.
    Hee, B.
    Wei, H.
    LaBadie, R.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2016, 99 : S38 - S38
  • [3] A phase 2 trial of the oral smoothened inhibitor glasdegib in refractory myelodysplastic syndromes (MDS)
    Sallman, David A.
    Komrokji, Rami S.
    Sweet, Kendra L.
    Mo, Qianxing
    McGraw, Kathy L.
    Duong, Vu H.
    Zhang, Ling
    Nardelli, Lisa Ann
    Padron, Eric
    List, Alan F.
    Lancet, Jeffrey E.
    LEUKEMIA RESEARCH, 2019, 81 : 56 - 61
  • [4] Evaluation of the effect of food and ketoconazole on the pharmacokinetics of the smoothened inhibitor PF-04449913 in healthy volunteers
    Shaik, M. Naveed
    LaBadie, Robert R.
    Rudin, Dan
    Levin, Wendy J.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 74 (02) : 411 - 418
  • [5] Absolute Oral Bioavailability of Glasdegib (PF-04449913), a Smoothened Inhibitor, in Randomized Healthy Volunteers
    Shaik, Naveed
    Hee, Brian
    Liang, Yali
    LaBadie, Robert Roland
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2019, 8 (07): : 895 - 902
  • [6] Evaluation of the effect of food and ketoconazole on the pharmacokinetics of the smoothened inhibitor PF-04449913 in healthy volunteers
    M. Naveed Shaik
    Robert R. LaBadie
    Dan Rudin
    Wendy J. Levin
    Cancer Chemotherapy and Pharmacology, 2014, 74 : 411 - 418
  • [7] Phase I study of glasdegib (PF-04449913), an oral smoothened inhibitor, in Japanese patients with select hematologic malignancies
    Minami, Yosuke
    Minami, Hironobu
    Miyamoto, Toshihiro
    Yoshimoto, Goichi
    Kobayashi, Yukio
    Munakata, Wataru
    Onishi, Yasushi
    Kobayashi, Masahiro
    Ikuta, Mari
    Chan, Geoffrey
    Woolfson, Adrian
    Ono, Chiho
    Shaik, Mohammed Naveed
    Fujii, Yosuke
    Zheng, Xianxian
    Naoe, Tomoki
    CANCER SCIENCE, 2017, 108 (08) : 1628 - 1633
  • [8] A Phase 2 Study of the Hedgehog Pathway Smoothened Inhibitor PF-04449913 to Reduce Relapse in High Risk Acute Leukemia and MDS Patients Following Allogeneic Stem Cell Transplantation
    Gutman, Jonathan A.
    Denoncourt, Emily
    Schatz, Derek
    Smith, Clayton
    Pollyea, Daniel Aaron
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2015, 21 (02) : S286 - S286
  • [9] Treatment with PF-04449913, an oral smoothened antagonist, in patients with myeloid malignancies: a phase 1 safety and pharmacokinetics study
    Martinelli, Giovanni
    Oehler, Vivian G.
    Papayannidis, Cristina
    Courtney, Rachel
    Shaik, M. Naveed
    Zhang, Xiaoxi
    O'Connell, Ashleigh
    McLachlan, Karen R.
    Zheng, Xianxian
    Radich, Jerald
    Baccarani, Michele
    Kantarjian, Hagop M.
    Levin, Wendy J.
    Cortes, Jorge E.
    Jamieson, Catriona
    LANCET HAEMATOLOGY, 2015, 2 (08): : E339 - E346
  • [10] The human Smoothened inhibitor PF-04449913 induces exit from quiescence and loss of multipotent Drosophila hematopoietic progenitor cells
    Giordani, Giorgia
    Barraco, Marilena
    Giangrande, Angela
    Martinelli, Giovanni
    Guadagnuolo, Viviana
    Simonetti, Giorgia
    Perini, Giovanni
    Bernardoni, Roberto
    ONCOTARGET, 2016, 7 (34) : 55313 - 55327
12345